- Home
- GDHG vs APVO Comparison
GDHG vs APVO Comparison
Compare GDHG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDHG
- APVO
- Stock Information
- Founded
- GDHG 2008
- APVO 2016
- Country
- GDHG China
- APVO United States
- Employees
- GDHG N/A
- APVO N/A
- Industry
- GDHG Services-Misc. Amusement & Recreation
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- GDHG Consumer Discretionary
- APVO Health Care
- Exchange
- GDHG Nasdaq
- APVO Nasdaq
- Market Cap
- GDHG 19.4M
- APVO 21.7M
- IPO Year
- GDHG 2023
- APVO N/A
- Fundamental
- Price
- GDHG $6.70
- APVO $1.50
- Analyst Decision
- GDHG
- APVO
- Analyst Count
- GDHG 0
- APVO 0
- Target Price
- GDHG N/A
- APVO N/A
- AVG Volume (30 Days)
- GDHG 32.9K
- APVO 5.2M
- Earning Date
- GDHG 07-11-2025
- APVO 11-06-2025
- Dividend Yield
- GDHG N/A
- APVO N/A
- EPS Growth
- GDHG N/A
- APVO N/A
- EPS
- GDHG N/A
- APVO N/A
- Revenue
- GDHG $16,666,899.00
- APVO N/A
- Revenue This Year
- GDHG N/A
- APVO N/A
- Revenue Next Year
- GDHG N/A
- APVO N/A
- P/E Ratio
- GDHG N/A
- APVO N/A
- Revenue Growth
- GDHG N/A
- APVO N/A
- 52 Week Low
- GDHG $2.40
- APVO $1.32
- 52 Week High
- GDHG $1,968.41
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- GDHG 43.05
- APVO 43.96
- Support Level
- GDHG $6.36
- APVO $1.50
- Resistance Level
- GDHG $7.70
- APVO $1.67
- Average True Range (ATR)
- GDHG 0.52
- APVO 0.12
- MACD
- GDHG -0.20
- APVO 0.03
- Stochastic Oscillator
- GDHG 42.33
- APVO 22.60
About GDHG Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.